➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Boehringer Ingelheim

Last Updated: July 4, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for LCB01-0371

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug LCB01-0371?

LCB01-0371 is an investigational drug.

There have been 8 clinical trials for LCB01-0371. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are Tuberculosis, Tuberculosis, Pulmonary, and [disabled in preview]. The leading clinical trial sponsors are LegoChem Biosciences, Inc and [disabled in preview].

There are two US patents protecting this investigational drug and nineteen international patents.

Recent Clinical Trials for LCB01-0371
A Mass Balance Study of LCB01-0371 After a Single Oral LCB01-0371 Dose With a [14C]LCB01-0371-microtraceLegoChem Biosciences, IncEarly Phase 1
A Clinical Study of LCB01-0371LegoChem Biosciences, IncPhase 2
IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male VolunteersLegoChem Biosciences, IncPhase 1

See all LCB01-0371 clinical trials

Clinical Trial Summary for LCB01-0371

Top disease conditions for LCB01-0371
Top clinical trial sponsors for LCB01-0371

See all LCB01-0371 clinical trials

US Patents for LCB01-0371

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LCB01-0371   Start Trial Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone pharmaceutical compositions thereof Legochem Biosciences, Inc. (Deajeon, KR)   Start Trial
LCB01-0371   Start Trial Method for preparing (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-- (substituted methyl)oxazolidin-2-one derivatives Legochem Biosciences, Inc. (Daejeon, KR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LCB01-0371

Drugname Country Document Number Estimated Expiration Related US Patent
LCB01-0371 Australia 2009297294 2028-09-24   Start Trial
LCB01-0371 Brazil PI0918964 2028-09-24   Start Trial
LCB01-0371 Canada 2737299 2028-09-24   Start Trial
LCB01-0371 China 102171207 2028-09-24   Start Trial
LCB01-0371 European Patent Office 2331529 2028-09-24   Start Trial
LCB01-0371 Spain 2526120 2028-09-24   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.